S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

TransMedics Group Stock Forecast, Price & News

-0.24 (-0.75 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $31.78
50-Day Range
MA: $28.01
52-Week Range
Now: $31.78
Volume1.22 million shs
Average Volume758,366 shs
Market Capitalization$863.18 million
P/E RatioN/A
Dividend YieldN/A
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion apparatus, optimization, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
TransMedics Group logo


TransMedics: Q4 Earnings Snapshot
March 2, 2021 |  finance.yahoo.com
TMDX Feb 2021 35.000 put
January 24, 2021 |  au.finance.yahoo.com
TMDX Feb 2021 30.000 call
January 24, 2021 |  au.finance.yahoo.com
TMDX Jul 2021 15.000 put
December 28, 2020 |  au.finance.yahoo.com
TransMedics Appoints Merilee Raines to Board of Directors
December 23, 2020 |  finance.yahoo.com
Is TMDX A Good Stock To Buy Now?
December 7, 2020 |  finance.yahoo.com
TransMedics Group EPS beats by $0.10, beats on revenue
November 4, 2020 |  seekingalpha.com
TransMedics Reports Third Quarter 2020 Financial Results
November 4, 2020 |  finance.yahoo.com
Austpro Closes Financing
October 29, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolNASDAQ:TMDX
Year FoundedN/A



Sales & Book Value

Annual Sales$23.60 million
Book Value$2.58 per share


Net Income$-33,550,000.00
Net Margins-131.35%


Market Cap$863.18 million
Next Earnings Date5/5/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.38 out of 5 stars

Medical Sector

652nd out of 1,968 stocks

Electromedical Equipment Industry

13th out of 61 stocks

Analyst Opinion: 2.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
-0.24 (-0.75 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TMDX News and Ratings via Email

Sign-up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

TransMedics Group (NASDAQ:TMDX) Frequently Asked Questions

Is TransMedics Group a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TransMedics Group stock.
View analyst ratings for TransMedics Group
or view top-rated stocks.

What stocks does MarketBeat like better than TransMedics Group?

Wall Street analysts have given TransMedics Group a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but TransMedics Group wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is TransMedics Group's next earnings date?

TransMedics Group is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for TransMedics Group

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) released its quarterly earnings results on Monday, March, 1st. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. TransMedics Group had a negative net margin of 131.35% and a negative trailing twelve-month return on equity of 38.95%.
View TransMedics Group's earnings history

How has TransMedics Group's stock been impacted by COVID-19 (Coronavirus)?

TransMedics Group's stock was trading at $13.62 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TMDX stock has increased by 133.3% and is now trading at $31.78.
View which stocks have been most impacted by COVID-19

What price target have analysts set for TMDX?

5 equities research analysts have issued twelve-month target prices for TransMedics Group's shares. Their forecasts range from $15.00 to $46.00. On average, they expect TransMedics Group's share price to reach $36.60 in the next year. This suggests a possible upside of 15.2% from the stock's current price.
View analysts' price targets for TransMedics Group
or view top-rated stocks among Wall Street analysts.

Who are TransMedics Group's key executives?

TransMedics Group's management team includes the following people:
  • Dr. Waleed H. Hassanein, Founder, MD, CEO, Pres & Director (Age 53, Pay $808.82k)
  • Mr. Stephen Gordon, CFO. Treasurer & Sec. (Age 53, Pay $491.92k)
  • Dr. Tamer I. Khayal, Chief Commercial Officer (Age 52, Pay $522.52k)
  • Mr. John F. Carey, VP of Operations (Age 56)
  • Mr. Ike Okonkwo, VP of Fin. & Accounting (Age 50)
  • Mr. Mark Anderson, Sr. Director of Technology Devel.
  • Mr. Brian Thomson, VP of HR (Age 53)

What is Waleed Hassanein's approval rating as TransMedics Group's CEO?

17 employees have rated TransMedics Group CEO Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among TransMedics Group's employees.

Who are some of TransMedics Group's key competitors?

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and The Walt Disney (DIS).

When did TransMedics Group IPO?

(TMDX) raised $75 million in an IPO on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.78%), Credit Suisse AG (5.55%), Emerald Advisers LLC (2.48%), Emerald Mutual Fund Advisers Trust (2.14%), Federated Hermes Inc. (1.68%) and Price T Rowe Associates Inc. MD (1.24%). Company insiders that own TransMedics Group stock include Abrams Capital Management, LP, David Weill, Edwin M Kania Jr, James R Tobin, John F Carey, John F Sullivan, Stephen Gordon and Tamer I Khayal.
View institutional ownership trends for TransMedics Group

Which institutional investors are selling TransMedics Group stock?

TMDX stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Price T Rowe Associates Inc. MD, Emerald Mutual Fund Advisers Trust, Northern Trust Corp, Bank of New York Mellon Corp, Barclays PLC, Charles Schwab Investment Management Inc., and Nuveen Asset Management LLC. Company insiders that have sold TransMedics Group company stock in the last year include Abrams Capital Management, LP, James R Tobin, John F Carey, John F Sullivan, and Stephen Gordon.
View insider buying and selling activity for TransMedics Group
or view top insider-selling stocks.

Which institutional investors are buying TransMedics Group stock?

TMDX stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Roubaix Capital LLC, Dimensional Fund Advisors LP, Emerald Advisers LLC, Belvedere Trading LLC, Wells Fargo & Company MN, Truist Financial Corp, and Aperio Group LLC. Company insiders that have bought TransMedics Group stock in the last two years include David Weill, and Edwin M Kania Jr.
View insider buying and selling activity for TransMedics Group
or or view top insider-buying stocks.

How do I buy shares of TransMedics Group?

Shares of TMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $31.78.

How much money does TransMedics Group make?

TransMedics Group has a market capitalization of $863.18 million and generates $23.60 million in revenue each year. The company earns $-33,550,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis.

How many employees does TransMedics Group have?

TransMedics Group employs 109 workers across the globe.

What is TransMedics Group's official website?

The official website for TransMedics Group is www.transmedics.com.

Where are TransMedics Group's headquarters?

TransMedics Group is headquartered at 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The company can be reached via phone at 978-552-0900 or via email at [email protected]

This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.